Harvard Bioscience Continues To Expect 2024 Gross Margin Of Approximately 60% And Adjusted EBITDA Margin In The Mid-teens
Portfolio Pulse from Benzinga Newsdesk
Harvard Bioscience projects its 2024 gross margin at around 60% and adjusted EBITDA margin in the mid-teens, with revenues expected to be roughly the same as in 2023. Growth in the second half of 2024 is anticipated, driven by new product launches and improvements in China.
May 07, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harvard Bioscience expects 2024 gross margin at 60% and adjusted EBITDA margin in the mid-teens, with stable revenues compared to 2023. Anticipates H2 growth from new products and China market.
The positive outlook on gross margin and adjusted EBITDA margin, along with expected revenue stability and growth in the second half of 2024, suggests a bullish sentiment for HBIO. The anticipation of new product commercializations and improvements in the China market are key drivers for this optimism.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100